2022.11.30
Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.
-
LanguageEnglish
-
Year and Month of Publication/Presentation01/11/2022
-
Type of ArticleOriginal Article
-
Invited ArticleNot Applicable
-
Journal NamePLoS One
-
Publication ClassificationAcademic Journal
-
Publisher / OrganizationPublic Library of Science
-
Volume, Issue,
Page NumbersVol. 7, No. 11, p. 17 -
Total Pages-
-
Author ContributionCo-authors
-
Authors and Co-authorsTanaka E, Inoue E, Shoji A, Nilsson J, Papagiannopoulos C, Dhanda D, Yoshizawa Y, Abe M, Saka K, Sugano E, Sugitani N, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M